BiotechTube
CytoTronics

CytoTronics

Cambridge, United States· Est.
cytotronics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $19.5M

Overview

Founded in 2019 and based in Cambridge, Massachusetts, CytoTronics is a private, platform-technology company focused on transforming cell biology discovery. Its core product, the Pixel™ system, integrates a semiconductor-to-live-cell interface with cloud-based analytics to provide unprecedented, data-rich insights into live cell function at scale. The company appears to be in an early-revenue stage, leveraging its technology to enable applications in neurological, cardiovascular, and oncology research, and has recently executed a strategic asset sale of a specific MEA technology to Axion BioSystems.

Neurological DiseasesCardiovascular DiseasesOncologyVascular Biology

Technology Platform

Pixel™ platform: a semiconductor-to-live-cell interface using a CMOS chip with thousands of sensors to enable multiplexed, longitudinal, single-cell resolution monitoring of viability, morphology, electrophysiology, and metabolism in any cell type, spheroid, or organoid. Integrated with cloud-based analytics software.

Funding History

2
Total raised:$19.5M
Series A$15M
Seed$4.5M

Opportunities

The growing adoption of complex, human-relevant cell models (like 3D organoids) in drug discovery creates a strong demand for tools that can provide deep, functional data from these systems.
CytoTronics' ability to multiplex electrophysiology with other critical readouts positions it uniquely in the high-content screening market, especially for neuroscience and cardiology applications where functional data is paramount.

Risk Factors

The company faces significant competition from established life science tool vendors and specialized electrophysiology firms.
Convincing researchers to adopt a new, integrated platform over familiar, modular methods presents a major market adoption challenge.
Scaling the manufacturing and commercial operations for a sophisticated hardware-software platform will require substantial capital and executional skill.

Competitive Landscape

CytoTronics competes with high-content screening imaging system vendors (e.g., PerkinElmer, Molecular Devices) and specialized electrophysiology companies (e.g., Axion BioSystems, MaxWell Biosystems). Its key differentiation is the integration of multiplexed functional sensing (especially electrophysiology) with morphological and viability data on a single, scalable semiconductor platform, a combination not fully offered by current market leaders.

More companies in United States →